US · RDY
Dr. Reddy's Laboratories Limited
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Hyderabad 500034
- Website
- drreddys.com
Price · as of 2025-03-31
$13.72
Market cap 11.97B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $0.10 | -99.27% |
| Intrinsic Value(DCF) | $17.70 | +29.01% |
| Graham-Dodd Method(GD) | $6.80 | -50.44% |
| Graham Formula(GF) | $18.40 | +34.11% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $6.09 | $3.37 | $1.47 | $0.70 | $2.10 |
| 2012 | $5.20 | $3.17 | $5.28 | $1.20 | $6.90 |
| 2013 | $6.96 | $4.67 | $3.37 | $9.90 | $6.10 |
| 2014 | $7.18 | $4.34 | $0.00 | $2.00 | $6.00 |
| 2015 | $9.82 | $5.44 | $5.43 | $2.30 | $5.80 |
| 2016 | $8.27 | $5.20 | $0.56 | $2.20 | $3.30 |
| 2017 | $7.56 | $4.23 | $0.37 | $1.80 | $0.00 |
| 2018 | $5.74 | $3.73 | $0.01 | $1.50 | $1.20 |
| 2019 | $7.06 | $4.72 | $0.08 | $2.30 | $4.10 |
| 2020 | $10.01 | $5.44 | $1.42 | $0.60 | $5.60 |
| 2021 | $14.07 | $7.08 | $0.01 | $0.00 | $0.00 |
| 2022 | $10.58 | $22.01 | $556.63 | $3.30 | $2,544.50 |
| 2023 | $11.14 | $7.95 | $267.91 | $5.10 | $13.50 |
| 2024 | $14.10 | $9.66 | $509.81 | $6.20 | $15.90 |
| 2025 | $15.45 | $10.45 | $72.76 | $6.80 | $18.40 |
AI valuation
Our deep-learning model estimates Dr. Reddy's Laboratories Limited's (RDY) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $0.10
- Current price
- $13.72
- AI upside
- -99.27%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$17.70
+29.01% upside
Graham-Dodd
$6.80
-50.44% upside
Graham Formula
$18.40
+34.11% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RDY | Dr. Reddy's Laboratories … | $13.72 | 11.97B | -24% | +29% | -50% | +34% | 19.94 | 3.42 | 3.51 | 11.69 | 1373.07 | 5.08 | 58.50% | 22.07% | 17.37% | 18.65% | 19.79% | 13.00% | 0.14 | 25.40 | 1.92 | 1.29 | 0.33 | 145.00% | 1661.00% | -3316.00% | 1.05% | 0.36 | 4.44% | 0.58% | 11.60% | 0.71% | 15.73 | 93.95 | 3.47 | 6.72 |
| BMRN | BioMarin Pharmaceutical I… | $61.73 | 11.86B | +37% | -52% | -36% | -40% | 32.84 | 1.88 | 3.56 | 18.32 | — | 2.02 | 77.13% | 16.56% | 10.83% | 5.94% | 7.50% | 4.79% | 0.10 | 48.95 | 5.21 | 3.25 | -1.25 | -1855.00% | 1287.00% | 5249.00% | 6.33% | 1.09 | 14.09% | 0.00% | 0.00% | 3.68% | 19.67 | 14.48 | 3.26 | 5.75 |
| EHC | Encompass Health Corporat… | $107.88 | 10.85B | -27% | -39% | -66% | -6% | 19.15 | 3.38 | 1.83 | 7.87 | 78.34 | 6.82 | 21.72% | 17.74% | 9.54% | 21.47% | 20.72% | 8.33% | 0.08 | 8.55 | 1.08 | 0.83 | 0.14 | 2444.00% | 1046.00% | 2190.00% | 4.04% | 1.41 | 10.83% | 0.65% | 12.50% | 24.52% | 10.50 | 25.17 | 1.86 | 3.05 |
| ELAN | Elanco Animal Health Inco… | $26.40 | 13.12B | +23% | -60% | -95% | — | -55.82 | 1.98 | 2.75 | 24.29 | — | -7.90 | 43.48% | 5.34% | -4.92% | -3.67% | 2.52% | -1.79% | 0.61 | 1.15 | 2.17 | 0.93 | 5.14 | -16912.00% | 622.00% | -2792.00% | 2.19% | 0.35 | 2.84% | 0.00% | 0.00% | 2.94% | 65.17 | 57.83 | 3.48 | 1.49 |
| ENSG | The Ensign Group, Inc. | $214.17 | 12.45B | -38% | +33% | -70% | -27% | 35.93 | 5.54 | 2.45 | 28.09 | 255.48 | 5.81 | 13.74% | 8.58% | 6.80% | 16.92% | 7.20% | 6.80% | 1.86 | 54.31 | 1.42 | 1.35 | 6.43 | 1406.00% | 1872.00% | 9620.00% | 3.00% | 0.63 | 8.15% | 0.12% | 4.20% | 0.29% | 36.77 | 43.03 | 3.15 | 4.02 |
| EXEL | Exelixis, Inc. | $44.06 | 11.81B | +59% | -51% | -50% | -3% | 14.24 | 5.16 | 4.80 | 11.13 | 24.57 | 5.31 | 96.39% | 37.59% | 33.73% | 35.53% | 55.80% | 27.02% | 0.08 | — | 3.56 | 3.32 | -0.34 | 5795.00% | 698.00% | 3322.00% | 7.58% | 2.18 | 64.97% | 0.00% | 0.00% | 11.04% | 11.76 | 12.15 | 4.42 | 12.01 |
| NBIX | Neurocrine Biosciences, I… | $132.25 | 13.27B | +32% | +46% | -57% | +4% | 27.52 | 4.05 | 4.60 | 18.16 | 65.61 | 4.05 | 98.18% | 21.64% | 16.73% | 16.38% | 20.21% | 11.46% | 0.13 | — | 3.39 | 2.92 | -0.45 | 4195.00% | 2145.00% | 3437.00% | 5.68% | 1.05 | 36.02% | 0.00% | 0.00% | 5.22% | 19.56 | 16.17 | 4.23 | 7.39 |
| RVMD | Revolution Medicines, Inc… | $102.02 | 19.72B | — | — | — | — | -17.08 | 11.84 | — | -16.01 | -25.80 | 12.38 | 0.00% | — | — | -58.07% | 1908.09% | -46.06% | 0.10 | -48.80 | 7.14 | 6.97 | 0.21 | 6620.00% | — | 6094.00% | -4.73% | -3.09 | 1474.57% | 0.00% | 0.00% | 0.00% | -14.76 | -19.10 | — | 13.58 |
| RVTY | Revvity, Inc. | $98.31 | 11.15B | +3% | -60% | -88% | -75% | 44.87 | 1.49 | 3.79 | 20.25 | — | -6.33 | 53.08% | 12.49% | 8.46% | 3.23% | 3.28% | 1.96% | 0.48 | 3.87 | 1.68 | 1.25 | 3.92 | -1369.00% | 367.00% | -617.00% | 4.70% | 0.44 | 5.17% | 0.30% | 13.60% | 7.89% | 37.63 | 26.40 | 4.70 | 1.74 |
| SOLV | Solventum Corporation | $74.20 | 12.87B | +72% | -56% | -45% | +7% | 8.17 | 2.52 | 1.53 | 6.62 | 3.68 | -3.91 | 53.47% | 26.20% | 18.69% | 38.86% | 20.41% | 10.82% | 1.00 | 6.29 | 1.23 | 0.61 | 1.63 | 22174.00% | 86.00% | -10124.00% | -0.08% | 0.12 | -0.10% | 0.00% | 0.00% | 24.32% | 7.73 | -1686.63 | 2.03 | 2.15 |
| VTRS | Viatris Inc. | $14.93 | 17.2B | +55% | -58% | — | — | -5.23 | 1.25 | 1.29 | -79.59 | -1.12 | -2.57 | 35.06% | -18.62% | -24.58% | -21.08% | -8.56% | -8.93% | 0.98 | -5.65 | 5.06 | 2.25 | -33.11 | 46604.00% | -298.00% | -201.00% | 10.54% | 1.20 | 6.49% | 3.05% | -16.00% | 8.39% | -11.82 | 16.25 | 2.20 | 0.88 |
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
- CEO
- Erez Israeli
- Employees
- 27.05K
- Beta
- 0.29
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($17.70 ÷ $13.72) − 1 = +29.01% (DCF, example).